Softwr

Healthcare · head to head

Clue vs Gleamer

Clue logo

Clue

Healthcare

Period and cycle tracking app owned by German company Biowink, positioned around science based tracking and a published stance against sharing data with law enforcement

From
Free
Rated
-
Full reviewWebsite
Gleamer logo

Gleamer

Healthcare

CE marked and FDA cleared imaging AI suite for bone trauma and chest, now owned by RadNet

From
On request
Rated
-
Full reviewWebsite

The short version

  • Only Clue has a free tier, so it costs nothing to try first.
  • Each has a real cost: Clue clues stated policy on not sharing data with law enforcement without a valid legal process is the companys own published position and legal interpretation, not an independent guarantee, and it can still be compelled to comply with a legally binding request under EU or other applicable law.; Gleamer radNet, an imaging provider that competes with many independent Gleamer customers, now owns the company and also owns the competing DeepHealth AI portfolio, so roadmap and pricing priorities are an open question for non-RadNet buyers.
  • They diverge on capability: Clue covers Cycle and symptom tracking, Gleamer covers BoneView.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Clue and Gleamer actually diverge.

Attributes where Clue and Gleamer differ
AttributeClueGleamer
Starting priceFreeOn request
Pricing modelFree with a Plus subscriptionquote
Free tierYesNo
PlatformsiOS, AndroidWeb, Cloud, On-premise

Identical on both: user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Clue

  • Cycle and symptom tracking
  • Cycle insights and patterns
  • Research partnerships
  • EU-based data hosting
  • Fertility and conception mode
  • Perimenopause and other life stage tracking

Only in Gleamer

  • BoneView
  • ChestView
  • BoneAge
  • BoneMetrics
  • LungCT and BoneCT
  • BreastView
  • Pixyl.Neuro
  • Gleamer Copilot

What people use each for

The jobs each tool is most often brought in to do.

Clue

  • Someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given Clues EU basis and published stance on law enforcement requestsnot Gleamer
  • A user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community contentnot Gleamer
  • A buyer comparing Clue directly against Flo on current published privacy policy language before choosing which app to trustnot Gleamer
  • Someone tracking perimenopause or other non-standard cycle stages that some period apps do not support wellnot Gleamer

Gleamer

  • An emergency department where junior doctors read plain films before radiology review and missed fractures are a recurring incident themenot Clue
  • An urgent care network standardising musculoskeletal reading quality across sites with variable radiology covernot Clue
  • A paediatric service automating bone age assessment to remove a slow manual atlas comparisonnot Clue
  • An orthopaedic service that needs automated limb alignment and measurement before surgical planning rather than manual measurement on the workstationnot Clue

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Clue

  • Clues stated policy on not sharing data with law enforcement without a valid legal process is the companys own published position and legal interpretation, not an independent guarantee, and it can still be compelled to comply with a legally binding request under EU or other applicable law.
  • Deeper cycle insights and predictions, the features most likely to justify tracking in the first place, are gated behind the Clue Plus subscription rather than fully free.
  • Being a smaller company than some competitors, Clue has less capital and legal resource to contest large-scale legal requests than a larger, better-funded rival might, despite its stated intent to do so.
  • Research partnerships using anonymised user data, while opt-in, still mean user-derived data can be used in ways beyond direct app functionality, and users should check current consent settings.
  • Cycle predictions rely on self-reported data and general population models, so accuracy for irregular cycles or specific medical conditions remains limited regardless of which app is used.

Gleamer

  • RadNet, an imaging provider that competes with many independent Gleamer customers, now owns the company and also owns the competing DeepHealth AI portfolio, so roadmap and pricing priorities are an open question for non-RadNet buyers.
  • The measured benefit is largest for less experienced readers, so a specialist musculoskeletal service will see far less improvement than the published reader studies suggest.
  • Cleared indications differ per module and per market, and the FDA cleared set is narrower than the CE marked European set, so an American buyer cannot rely on European reference sites.
  • Each additional module adds alert volume into the same worklist, and departments running several Gleamer algorithms report needing local threshold tuning to keep radiologist trust.
  • Pricing is per exam and not published, which makes budgeting difficult for an emergency department whose plain film volume swings seasonally.

Pricing, plan by plan

Clue

Free
  • Clue Plus$9.99/month
    • Free tier covers core cycle tracking, logging and basic predictions
    • Clue Plus adds deeper cycle insights, extended predictions and personalised content
    • Annual Plus plans typically offered at a lower effective monthly rate

Gleamer

On request
  • Gleamer Copilot$undefined/year
    • Priced per exam analysed or as an annual volume subscription
    • Modules licensed individually or bundled as Copilot
    • Cleared and CE marked indication differs per module and per market

Which should you pick?

Choose Clue if

  • You need cycle and symptom tracking.
  • You want to start without paying.
  • You work on iOS, Android.
  • You also want cycle insights and patterns.
Clue review

Choose Gleamer if

  • You need boneview.
  • You work on Web, Cloud, On-premise.
  • You also want chestview.
Gleamer review

Questions people ask

Is Clue or Gleamer better?
Neither clearly leads. Clue starts at Free and Gleamer at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Clue or Gleamer?
Clue has a free tier; the other does not. Paid plans start at Free for Clue and On request for Gleamer.
Does Clue or Gleamer run on more platforms?
Clue runs on iOS, Android. Gleamer runs on Web, Cloud, On-premise.
Can I use Clue for free?
Yes. Clue has a free tier, so you can try it without paying. Gleamer starts at On request.
What is Clue best used for?
Clue is most often used for someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given clues eu basis and published stance on law enforcement requests, a user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community content, a buyer comparing clue directly against flo on current published privacy policy language before choosing which app to trust, someone tracking perimenopause or other non-standard cycle stages that some period apps do not support well. Of those, someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given clues eu basis and published stance on law enforcement requests and a user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community content are not what Gleamer is typically brought in for.
What can Clue do that Gleamer cannot?
Clue covers Cycle and symptom tracking, Cycle insights and patterns, Research partnerships, EU-based data hosting. Gleamer covers BoneView, ChestView, BoneAge, BoneMetrics.

Answered from the vendors’ own pages

Clue: Does Clue share data with law enforcement?

Clue publishes a policy stating it does not share health data with law enforcement or public authorities without a legally binding request and states it will challenge requests it considers improper. This is the companys stated position; verify the current policy directly for specifics.

Gleamer: Who owns Gleamer?

RadNet agreed to acquire Gleamer in February 2026 for around two hundred and fifteen million euros upfront. RadNet also owns DeepHealth, a competing AI portfolio.

Clue: Why does Clue emphasise being an EU company?

Clue operates under EU GDPR data protection rules and states this legal basis makes it harder for authorities outside the EU, including US authorities, to compel data disclosure than for a company based in the US.

Gleamer: Is BoneView FDA cleared?

Yes, BoneView holds 510(k) clearance including for paediatric fracture detection, but the cleared finding set is narrower than the CE marked indication in Europe.

Clue: Is Clue free?

Core cycle tracking, logging and basic predictions are free. Deeper insights and extended predictions require Clue Plus.

Gleamer: What does the evidence actually show?

Multi-reader studies reported improved reader sensitivity for fracture detection and fewer false negatives, with the gain concentrated among less experienced readers in emergency settings.

Gleamer: Can I buy just BoneView?

Yes, modules are licensed individually, though the commercial pitch is now the Copilot bundle across modalities.

Share

Related pages

More on Clue

More on Gleamer

Keep looking

Other head to heads